Abstract
Summary
According to our LPI (LP Information) latest study, the global Neurological Disorder Drugs market size was valued at US$ 1918.7 million in 2023. With growing demand in downstream market, the Neurological Disorder Drugs is forecast to a readjusted size of US$ 3513.2 million by 2030 with a CAGR of 9.0% during review period.
The research report highlights the growth potential of the global Neurological Disorder Drugs market. Neurological Disorder Drugs are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Neurological Disorder Drugs. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Neurological Disorder Drugs market.
Several government initiatives across various countries to educate masses about the rise of various diseases and increasing healthcare sector producing new drugs are the prime reasons for growth of neurological disorder drugs market. European Parkinson’s Disease Association, in Europe is actively supporting research and development by campaigning to raise awareness, and providing medication to patients is boosting the overall neurological disorder drugs market. This region is also witnessing rising focus on research and development programs that will help in producing affordable and effective drugs. The countries are collectively spending on developing neurological disorder drugs thus, improving the revenue of the market during the forecast period.
Staggering increase in brain altering disorders such as Alzheimer’s, epilepsy, Parkinson’s, cerebrovascular, and sclerosis are promoting the pharmaceutical firms to tap into the significantly growing neurological disorder drugs market. This will potentially supplement the market growth in the coming years. Rise of several innovative drugs to manage these diseases will swell up the investments in the market. Increasing number of clinical trials are another reason boosting the market. Rise in geriatric population along with patients with strokes, migraines, and headaches leading to cerebrovascular diseases are likely to augment the growth of the market.
Key Features:
The report on Neurological Disorder Drugs market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Neurological Disorder Drugs market. It may include historical data, market segmentation by Type (e.g., Antipsychotic, Hypnotic & Sedative), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Neurological Disorder Drugs market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Neurological Disorder Drugs market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Neurological Disorder Drugs industry. This include advancements in Neurological Disorder Drugs technology, Neurological Disorder Drugs new entrants, Neurological Disorder Drugs new investment, and other innovations that are shaping the future of Neurological Disorder Drugs.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Neurological Disorder Drugs market. It includes factors influencing customer ' purchasing decisions, preferences for Neurological Disorder Drugs product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Neurological Disorder Drugs market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Neurological Disorder Drugs market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Neurological Disorder Drugs market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Neurological Disorder Drugs industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Neurological Disorder Drugs market.
Market Segmentation:
Neurological Disorder Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
Antipsychotic
Hypnotic & Sedative
Analgesics
Anticoagulants
Others
Segmentation by application
Hospital
Clinic
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
GlaxoSmithKline
Merck & Co.
Bayer
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceutical
The research report highlights the growth potential of the global Neurological Disorder Drugs market. Neurological Disorder Drugs are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Neurological Disorder Drugs. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Neurological Disorder Drugs market.
Several government initiatives across various countries to educate masses about the rise of various diseases and increasing healthcare sector producing new drugs are the prime reasons for growth of neurological disorder drugs market. European Parkinson’s Disease Association, in Europe is actively supporting research and development by campaigning to raise awareness, and providing medication to patients is boosting the overall neurological disorder drugs market. This region is also witnessing rising focus on research and development programs that will help in producing affordable and effective drugs. The countries are collectively spending on developing neurological disorder drugs thus, improving the revenue of the market during the forecast period.
Staggering increase in brain altering disorders such as Alzheimer’s, epilepsy, Parkinson’s, cerebrovascular, and sclerosis are promoting the pharmaceutical firms to tap into the significantly growing neurological disorder drugs market. This will potentially supplement the market growth in the coming years. Rise of several innovative drugs to manage these diseases will swell up the investments in the market. Increasing number of clinical trials are another reason boosting the market. Rise in geriatric population along with patients with strokes, migraines, and headaches leading to cerebrovascular diseases are likely to augment the growth of the market.
Key Features:
The report on Neurological Disorder Drugs market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Neurological Disorder Drugs market. It may include historical data, market segmentation by Type (e.g., Antipsychotic, Hypnotic & Sedative), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Neurological Disorder Drugs market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Neurological Disorder Drugs market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Neurological Disorder Drugs industry. This include advancements in Neurological Disorder Drugs technology, Neurological Disorder Drugs new entrants, Neurological Disorder Drugs new investment, and other innovations that are shaping the future of Neurological Disorder Drugs.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Neurological Disorder Drugs market. It includes factors influencing customer ' purchasing decisions, preferences for Neurological Disorder Drugs product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Neurological Disorder Drugs market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Neurological Disorder Drugs market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Neurological Disorder Drugs market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Neurological Disorder Drugs industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Neurological Disorder Drugs market.
Market Segmentation:
Neurological Disorder Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
Antipsychotic
Hypnotic & Sedative
Analgesics
Anticoagulants
Others
Segmentation by application
Hospital
Clinic
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
GlaxoSmithKline
Merck & Co.
Bayer
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceutical
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Neurological Disorder Drugs Market Size 2019-2030
2.1.2 Neurological Disorder Drugs Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Neurological Disorder Drugs Segment by Type
2.2.1 Antipsychotic
2.2.2 Hypnotic & Sedative
2.2.3 Analgesics
2.2.4 Anticoagulants
2.2.5 Others
2.3 Neurological Disorder Drugs Market Size by Type
2.3.1 Neurological Disorder Drugs Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Neurological Disorder Drugs Market Size Market Share by Type (2019-2024)
2.4 Neurological Disorder Drugs Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.5 Neurological Disorder Drugs Market Size by Application
2.5.1 Neurological Disorder Drugs Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Neurological Disorder Drugs Market Size Market Share by Application (2019-2024)
3 Neurological Disorder Drugs Market Size by Player
3.1 Neurological Disorder Drugs Market Size Market Share by Players
3.1.1 Global Neurological Disorder Drugs Revenue by Players (2019-2024)
3.1.2 Global Neurological Disorder Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Neurological Disorder Drugs Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Neurological Disorder Drugs by Regions
4.1 Neurological Disorder Drugs Market Size by Regions (2019-2024)
4.2 Americas Neurological Disorder Drugs Market Size Growth (2019-2024)
4.3 APAC Neurological Disorder Drugs Market Size Growth (2019-2024)
4.4 Europe Neurological Disorder Drugs Market Size Growth (2019-2024)
4.5 Middle East & Africa Neurological Disorder Drugs Market Size Growth (2019-2024)
5 Americas
5.1 Americas Neurological Disorder Drugs Market Size by Country (2019-2024)
5.2 Americas Neurological Disorder Drugs Market Size by Type (2019-2024)
5.3 Americas Neurological Disorder Drugs Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Neurological Disorder Drugs Market Size by Region (2019-2024)
6.2 APAC Neurological Disorder Drugs Market Size by Type (2019-2024)
6.3 APAC Neurological Disorder Drugs Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Neurological Disorder Drugs by Country (2019-2024)
7.2 Europe Neurological Disorder Drugs Market Size by Type (2019-2024)
7.3 Europe Neurological Disorder Drugs Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Neurological Disorder Drugs by Region (2019-2024)
8.2 Middle East & Africa Neurological Disorder Drugs Market Size by Type (2019-2024)
8.3 Middle East & Africa Neurological Disorder Drugs Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Neurological Disorder Drugs Market Forecast
10.1 Global Neurological Disorder Drugs Forecast by Regions (2025-2030)
10.1.1 Global Neurological Disorder Drugs Forecast by Regions (2025-2030)
10.1.2 Americas Neurological Disorder Drugs Forecast
10.1.3 APAC Neurological Disorder Drugs Forecast
10.1.4 Europe Neurological Disorder Drugs Forecast
10.1.5 Middle East & Africa Neurological Disorder Drugs Forecast
10.2 Americas Neurological Disorder Drugs Forecast by Country (2025-2030)
10.2.1 United States Neurological Disorder Drugs Market Forecast
10.2.2 Canada Neurological Disorder Drugs Market Forecast
10.2.3 Mexico Neurological Disorder Drugs Market Forecast
10.2.4 Brazil Neurological Disorder Drugs Market Forecast
10.3 APAC Neurological Disorder Drugs Forecast by Region (2025-2030)
10.3.1 China Neurological Disorder Drugs Market Forecast
10.3.2 Japan Neurological Disorder Drugs Market Forecast
10.3.3 Korea Neurological Disorder Drugs Market Forecast
10.3.4 Southeast Asia Neurological Disorder Drugs Market Forecast
10.3.5 India Neurological Disorder Drugs Market Forecast
10.3.6 Australia Neurological Disorder Drugs Market Forecast
10.4 Europe Neurological Disorder Drugs Forecast by Country (2025-2030)
10.4.1 Germany Neurological Disorder Drugs Market Forecast
10.4.2 France Neurological Disorder Drugs Market Forecast
10.4.3 UK Neurological Disorder Drugs Market Forecast
10.4.4 Italy Neurological Disorder Drugs Market Forecast
10.4.5 Russia Neurological Disorder Drugs Market Forecast
10.5 Middle East & Africa Neurological Disorder Drugs Forecast by Region (2025-2030)
10.5.1 Egypt Neurological Disorder Drugs Market Forecast
10.5.2 South Africa Neurological Disorder Drugs Market Forecast
10.5.3 Israel Neurological Disorder Drugs Market Forecast
10.5.4 Turkey Neurological Disorder Drugs Market Forecast
10.5.5 GCC Countries Neurological Disorder Drugs Market Forecast
10.6 Global Neurological Disorder Drugs Forecast by Type (2025-2030)
10.7 Global Neurological Disorder Drugs Forecast by Application (2025-2030)
11 Key Players Analysis
11.1 Novartis
11.1.1 Novartis Company Information
11.1.2 Novartis Neurological Disorder Drugs Product Offered
11.1.3 Novartis Neurological Disorder Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Novartis Main Business Overview
11.1.5 Novartis Latest Developments
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Company Information
11.2.2 GlaxoSmithKline Neurological Disorder Drugs Product Offered
11.2.3 GlaxoSmithKline Neurological Disorder Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 GlaxoSmithKline Main Business Overview
11.2.5 GlaxoSmithKline Latest Developments
11.3 Merck & Co.
11.3.1 Merck & Co. Company Information
11.3.2 Merck & Co. Neurological Disorder Drugs Product Offered
11.3.3 Merck & Co. Neurological Disorder Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Merck & Co. Main Business Overview
11.3.5 Merck & Co. Latest Developments
11.4 Bayer
11.4.1 Bayer Company Information
11.4.2 Bayer Neurological Disorder Drugs Product Offered
11.4.3 Bayer Neurological Disorder Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Bayer Main Business Overview
11.4.5 Bayer Latest Developments
11.5 AstraZeneca
11.5.1 AstraZeneca Company Information
11.5.2 AstraZeneca Neurological Disorder Drugs Product Offered
11.5.3 AstraZeneca Neurological Disorder Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 AstraZeneca Main Business Overview
11.5.5 AstraZeneca Latest Developments
11.6 Boehringer Ingelheim
11.6.1 Boehringer Ingelheim Company Information
11.6.2 Boehringer Ingelheim Neurological Disorder Drugs Product Offered
11.6.3 Boehringer Ingelheim Neurological Disorder Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Boehringer Ingelheim Main Business Overview
11.6.5 Boehringer Ingelheim Latest Developments
11.7 Teva Pharmaceutical
11.7.1 Teva Pharmaceutical Company Information
11.7.2 Teva Pharmaceutical Neurological Disorder Drugs Product Offered
11.7.3 Teva Pharmaceutical Neurological Disorder Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Teva Pharmaceutical Main Business Overview
11.7.5 Teva Pharmaceutical Latest Developments
12 Research Findings and Conclusion